Clinical trials: Urinary Bladder Disease
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
Urothelial Carcinoma
HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
This study is being done to learn about urothelial cancers that make HER2 and how that affects treatment choices for participants with urothelial cancer.
- Trial name
- NCT05902494
- Where
- 23 sites in United States, Austria and 2 more
- Volunteers
- 389 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Overactive Bladder
A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency
This study is designed to assess the efficacy of a flexible dose regimen of fesoterodine on micturition related nocturnal urgency episodes.
- Trial name
- NCT00911937
- Testing
- Fesoterodine
- Where
- 112 sites in United States
- Volunteers
- 963 people
- Sponsor
- Pfizer
Non-Muscle Invasive Bladder Neoplasms
A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free…
- Trial name
- Nova-sTAR (NCT07309445)
- Where
- 19 sites in United States
- Volunteers
- 150 people
- Sponsor
- Janssen Research & Development, LLC
Urinary Bladder, Overactive
Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
- Trial name
- VIBRANT (NCT00573508)
- Testing
- Solifenacin Succinate
- Where
- 59 sites in United States
- Volunteers
- 768 people
- Sponsor
- Astellas Pharma Inc
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Bladder Cancer, Urocystitis
A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China
The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder cancer by comparing with clinical standard method…
- Conditions
- Bladder Cancer, Urocystitis, Urinary Bladder Stone, Urothelial Carcinoma
- Trial name
- NCT05337189
- Testing
- Urine DNA methylation analysis, medical imaging and/or cystoscopy and/or pathological examination
- Where
- China
- Volunteers
- 482 people, healthy volunteers welcome
- Sponsor
- Creative Biosciences (Guangzhou) Co., Ltd.
Carcinoma in Situ, Non Muscle Invasive Bladder Cancer
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
This is a Phase II pilot study to explore the effect of intravesical TMX-101 in patients with CIS bladder cancer, as assessed by histology and cytology after TMX-101 treatment.
- Trial name
- NCT01731652
- Testing
- TMX-101
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Telormedix SA
Superficial Bladder Cancer
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Gemcitabine has been shown to be highly effective and well tolerated in the first and second line therapy, as a single agent or in combination therapy for treatment of metastatic transitional cell carcinoma.
- Trial name
- NCT00192049
- Testing
- Gemcitabine, mitomycin C
- Where
- 5 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder, Urinary Incontinence
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urge Incontinence
- Trial name
- SOLAR (NCT00337558)
- Testing
- Solifenacin succinate, Simplified bladder training
- Where
- 64 sites in Australia, Belgium and 9 more
- Volunteers
- 643 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world…
- Trial name
- NCT05067478
- Testing
- Vibegron
- Where
- 64 sites in United States
- Volunteers
- 403 people
- Sponsor
- Urovant Sciences GmbH
LUTS, Benign Prostatic Hyperplasia
Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin
The purpose of this study is to investigate the pharmacokinetic drug interaction between Solifenacin and Tamsulosin in healthy male volunteers.
- Conditions
- LUTS, Benign Prostatic Hyperplasia, Overactive Bladder
- Trial name
- NCT02180997
- Testing
- Tamsulosin, Solifenacin, Tamsulosin and solifenacin
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Cholangiocarcinoma
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04742959
- Testing
- TT-00420, Nab-Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 203 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Ovarian Clear Cell Carcinoma, Endometrial Cancer
TR115 in ARID1A-Mutated Advanced Solid Tumors
This is an open-label, multicenter, exploratory Phase II study to evaluate the efficacy and safety of TR115, an EZH2 inhibitor, in patients with advanced solid tumors carrying ARID1A gene mutations.
- Conditions
- Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer
- Trial name
- NCT07793318
- Testing
- TR115
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tarapeutics Science Inc.
Overactive Bladder Syndrome, Urinary Urge Incontinence
Cycling Study With the Axonics System
A prospective, multi-center, study comparing continuous sacral neuromodulation (SNM) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the Axonics System.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation
- Trial name
- NCT05543382
- Testing
- Axonics System
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Axonics, Inc.
Overactive Bladder, Fecal Incontinence
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
To collect physiological signals at several timepoints during the therapy evaluation period.
- Conditions
- Overactive Bladder, Fecal Incontinence, Urinary Retention
- Trial name
- PEER 2 (NCT05200923)
- Testing
- Sacral Neuromodulation
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- MedtronicNeuro
Bladder Cancer
Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer
The objective of this study is to establish the performance characteristics of an assay that detects the recurrence of bladder cancer in patients previously diagnosed with bladder cancer.
- Trial name
- NCT03125460
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 424 people
- Sponsor
- Cepheid
Overactive Bladder (OAB)
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
- Trial name
- NCT02294396
- Testing
- Mirabegron tablet, Solifenacin tablet, Propiverine tablet
- Where
- 7 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Astellas Pharma Inc
Bladder Cancer
Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer
The purpose of this study is to evaluate efficacy of gemcitabine and cisplatin combined with either radical cystectomy or radiotherapy in the treatment of bladder cancer.
- Trial name
- NCT00490880
- Testing
- gemcitabine, cisplatin, radical cystectomy
- Where
- Poland
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company